We are live on ! Find out more
LOGC

LogicBio Therapeutics, Inc. Common Stock
LOGC

Delisted

LOGC was delisted on the 15th of November, 2022.

Back to rankings

46 hedge funds and large institutions have $8.66M invested in LogicBio Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 14 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% less funds holding

Funds holding: 57 → 46 (-11)

57% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 14

71% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 14

77% less capital invested

Capital invested by funds: $37M → $8.66M (-$28.3M)

Holders
46
Holders Change
-11
Holders Change %
-19.3%
% of All Funds
0.73%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
14
Closed
14
Calls
$14K
Puts
–
Net Calls
+$14K
Net Calls Change
+$41K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$504K
2
VF
Virtu Financial
New York
+$59.4K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$55.2K
4
Bank Julius Baer & Co
Bank Julius Baer & Co
Switzerland
+$21.3K
5
FT
Fiduciary Trust
Massachusetts
+$11K

Top Sellers

Rank Fund Capital Flow
1
SC
Samlyn Capital
New York
-$3.49M
2
Franklin Resources
Franklin Resources
California
-$752K
3
PIM
Platinum Investment Management
Australia
-$740K
4
EP
Eversept Partners
New York
-$672K
5
PVI
Pura Vida Investments
New York
-$532K
Name Holding Trade Value Shares
Change 		Change in
Stake
Commonwealth Equity Services
26
Commonwealth Equity Services
Massachusetts
$8K – – –
TRCT
27
Tower Research Capital (TRC)
New York
$8K +$10.5K +9,547 +317%
IBOK
28
Independence Bank of Kentucky
Kentucky
$7K -$2.94K -2,675 -21%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$7K – – –
Barclays
30
Barclays
United Kingdom
$6K -$6.93K -6,313 -42%
Osaic Holdings
31
Osaic Holdings
Arizona
$3K +$91 +83 +2%
Bank of America
32
Bank of America
North Carolina
$1K -$4.21K -3,835 -82%
APC
33
Aspire Private Capital
North Carolina
$1K – – –
Group One Trading
34
Group One Trading
Illinois
$1K – – –
LWANC
35
Laurel Wealth Advisors (North Carolina)
North Carolina
$1K – – –
US Bancorp
36
US Bancorp
Minnesota
$1K – – –
Wells Fargo
37
Wells Fargo
California
$1K +$3 +3 +0.2%
Federated Hermes
38
Federated Hermes
Pennsylvania
$1K +$577 +526 New
FDCDDQ
39
Federation des caisses Desjardins du Quebec
Quebec, Canada
$612 – – –
BNP Paribas Financial Markets
40
BNP Paribas Financial Markets
France
$171 -$203 -185 -42%
SC
41
Samlyn Capital
New York
– -$3.49M -1,511,417 Closed
PIM
42
Platinum Investment Management
Australia
– -$740K -320,273 Closed
EP
43
Eversept Partners
New York
– -$672K -291,101 Closed
PVI
44
Pura Vida Investments
New York
– -$532K -230,121 Closed
Verition Fund Management
45
Verition Fund Management
Connecticut
– -$262K -113,532 Closed
Dimensional Fund Advisors
46
Dimensional Fund Advisors
Texas
– -$56K -24,378 Closed
William Blair & Company
47
William Blair & Company
Illinois
– -$51K -21,950 Closed
Citadel Advisors
48
Citadel Advisors
Florida
– -$20.4K -18,600 Closed
Charles Schwab
49
Charles Schwab
California
– -$27K -11,498 Closed
Connor, Clark & Lunn Investment Management (CC&L)
50
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$25K -10,974 Closed
1
2
3

LOGC Hedge Fund Activity: Q1 2022 in Review

46 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q1 2022, worth a combined $8.66M — down 77% from $37M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of LOGC and 4 opened new positions — a net loss of 10 holders — while 14 trimmed existing stakes and 6 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $504K. The largest seller was Samlyn Capital, exiting entirely with an estimated $3.49M sold.

  • 46 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q1 2022, down from 57 in Q4 2021.
  • Funds reported $8.66M of LogicBio Therapeutics, Inc. Common Stock stock for Q1 2022, down 77% quarter-over-quarter.
  • 4 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q1 2022 and 14 closed out, a net change of -10 holders.
  • The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q1 2022 was Renaissance Technologies, an estimated $504K added.
  • The largest LogicBio Therapeutics, Inc. Common Stock seller in Q1 2022 was Samlyn Capital, an estimated $3.49M sold.

Based on aggregated 13F filings for Q1 2022.